Relationship between CHADS2 score and ischemic stroke during rhythm control therapy for paroxysmal atrial fibrillation

International Heart Journal

Volumn 51, Issue 1, 2010, Pages 24-29

  Komatsu, Takashi ^a   Tachibana, Hideaki ^a   Sato, Yoshihiro ^a   Ozawa, Masato ^a   Kunugida, Fusanori ^a   Orii, Makoto ^a   Nakamura, Motoyuki ^a  

^a IWATE MEDICAL UNIVERSITY   (Japan)

Author keywords

Antiarrhythmic therapy; Anticoagulant therapy; CHADS2 score; Paroxysmal atrial fibrillation; Thromboembolism

Indexed keywords

ACETYLSALICYLIC ACID; AMIODARONE; ANTIARRHYTHMIC AGENT; APRINDINE; BEPRIDIL; CIBENZOLINE; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; DISOPYRAMIDE; FLECAINIDE; PILSICAINIDE; WARFARIN; ANTICOAGULANT AGENT;

AGED; ANTICOAGULANT THERAPY; ARTICLE; CARDIOVERSION; CEREBROVASCULAR ACCIDENT; CHADS 2 SCORE; CONTROLLED STUDY; DRUG EFFICACY; FEMALE; FOLLOW UP; HEART ATRIUM FIBRILLATION; HIGH RISK POPULATION; HUMAN; INTERNATIONAL NORMALIZED RATIO; JAPANESE; MAJOR CLINICAL STUDY; MALE; PAROXYSMAL HEART ATRIUM FIBRILLATION; PREDICTION; PRIORITY JOURNAL; PROTHROMBIN TIME; RECURRENT DISEASE; RETROSPECTIVE STUDY; SCORING SYSTEM; THROMBOEMBOLISM; BRAIN INFARCTION; HEART PACING; HOSPITALIZATION; JAPAN; MIDDLE AGED;

AGED; AGED, 80 AND OVER; ANTICOAGULANTS; ATRIAL FIBRILLATION; BRAIN INFARCTION; CARDIAC PACING, ARTIFICIAL; FEMALE; HUMANS; JAPAN; MALE; MIDDLE AGED; RETROSPECTIVE STUDIES; SEVERITY OF ILLNESS INDEX; WARFARIN;

EID: 76749088868     PISSN: 13492365     EISSN: 13493299     Source Type: Journal    
DOI: 10.1536/ihj.51.24     Document Type: Article

References (32)

1. Chugh SS, Blackshear JL, Shen WK, Hammill SC, Gersh BJ. Epidemiology and natural history of atrial fibrillation: clinical implications. J Am Coll Cardiol 2001; 37: 371-8. (Review)
2. Inoue H, Fujiki A, Origasa H, et al. Prevalence of atrial fibrillation in the general population of Japan: an analysis based on periodic health examination. Int J Cardiol 2009; 137: 102-7.
3. Wolf PA, Abbott RD, Kannel WB. Atrial fibrillation: a major contributor to stroke in the elderly. The Framingham Study. Arch Intern Med 1987; 147: 1561-4.
4. Dries DL, Exner DV, Gersh BJ, Domanski MJ, Waclawiw MA, Stevenson LW. Atrial fibrillation is associated with an increased risk for mortality and heart failure progression in patients with asymptomatic and symptomatic left ventricular systolic dysfunction: a retrospective analysis of the SOLVD trials. Studies of Left Ventricular Dysfunction. J Am Coll Cardiol 1998; 32: 695-703.
5. Fuster V, Rydén LE, Cannom DS, et al. ACC/AHA/ESC 2006 Guidelines for the Management of Patients with Atrial Fibrillation: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines and the European Society of Cardiology Committee for Practice Guidelines (Writing Committee to Revise the 2001 Guidelines for the Management of Patients With Atrial Fibrillation): developed in Collaboration With the European Heart Rhythm Association and the Heart Rhythm Society. Circulation 2006; 114: e257-354.
6. Sopher SM, Camm AJ. Attial fibrillation: maintenance of sinus rhythm versus rate control. Am J Cardiol 1996; 77: 24A-37A. (Review)
7. Diabetes Mellitus Diagnostic Criteria Committee. Report by the Diabetes Mellitus Classification and Diagnostic Criteria Committee. J Jpn Diabetes Soc 1999; 42: 385.
8. Whitworth JA, World Health Organization, International Society of Hypertension Writing Group. 2003 World Health Organization (WHO)/Intemational Society of Hypertension (ISH) statement on management of hypertension. J Hypertens 2003; 21: 1983-92.
9. Komatsu T, Sato Y, Tachibana H, et al. Efficacy of long-term flecainide therapy in patients with paroxysmal atrial fibrillation: analysis based on time of onset. J Arrhythmia 2006; 22: 37-43.
10. Komatsu T, Nakamura S, Suzuki O, Horiuchi D, Yomogida K, Okumura K. Long-term prognosis of the patients with paroxysmal atrial fibrillation depends on their response to antiarrhythmic therapy. Circ J 2004; 68: 729-33.
11. Komatsu T, Ozawa M, Tachibana H, Sato Y, Orii M, Nakamura M. Combination therapy with amiodarone and enalapril in patients with paroxysmal atrial fibrillation prevents the development of structural atrial remodeling. Int Heart J 2008; 49: 435-47.
12. Kodama I, Aizawa Y, Inoue H, Ohe T, Okumura K, Ogawa S, et al. (The Japanese Circulation Society Joint Study Group) Guidelines for the pharmacologic treatment of arrhythmias. Circ J 2004; 68 (suppl IV): 981-1053. (in Japanese)
13. Petersen P, Boysen G, Godtfredsen J, Andersen ED, Andersen B. Placebo-controlled, randomized trial of warfarin and aspirin for prevention of thromboembolic complications in chronic atrial fibrillation. The Copenhagen AFASAK study. Lancet 1989; 1: 175-9.
14. Warfarin versus aspirin for prevention of thromboembolism in atrial fibrillation: Stroke Prevention in Atrial Fibrillation II Study. Lancet 1994; 343: 687-91.
15. Connolly SJ, Laupacis A, Gent M, Roberts RS, Cairns JA, Joyner C. Canadian Atrial Fibrillation Anticoagulation (CAFA) Study. J Am Coll Cardiol 1991; 18: 349-55.
16. The effect of low-dose warfarin on the risk of stroke in patients with nonrheumatic atrial fibrillation. The Boston Area Anticoagulation Trial for Atrial Fibrillation Investigators. N Engl J Med 1990; 323: 1505-11.
17. Cardiogenic brain embolism. Cerebral Embolism Task Force. Arch Neurol 1986; 43: 71-84. (Review)
18. Stroke Prevention in Atrial Fibrillation Study. Final results. Circulation 1991; 84: 527-39.
19. Hart RG, Benavente O, McBride R, Pearce LA. Antithrombotic therapy to prevent stroke in patients with atrial fibrillation: a meta-analysis. Ann Intern Med 1999; 131:492-501.
20. Tomita F, Kohya T, Sakurai M, et al. Prevalence and clinical characteristics of patients with atrial fibrillation: analysis of 20,000 cases in Japan. Jpn Circ J 2000; 64: 653-8.
21. Sato H, Ishikawa K, Kitabatake A, et al. Low-dose aspirin for prevention of stroke in low-risk patients with atrial fibrillation: Japan Atrial Fibrillation Stroke Trial. Stroke 2006; 37: 447-51.
22. Hart RG, Pearce LA, McBride R, Rothbart RM, Asinger RW. Factors associated with ischemic stroke during aspirin therapy in atrial fibrillation: analysis of 2012 participants in the SPAF I-III clinical trials. The Stroke Prevention in Atrial Fibrillation (SPAF) Investigators. Stroke 1999; 30: 1223-9.
23. van Walraven WC, Hart RG, Wells GA, et al. A clinical prediction rule to identify patients with atrial fibrillation and a low risk for stroke while taking aspirin. Arch Intern Med 2003; 163: 936-43.
24. Gage BF, Waterman AD, Shannon W, Boechler M, Rich MW, Radford MJ. Validation of clinical classification schemes for predicting stroke: results from the National Registry of Atrial Fibrillation. JAMA 2001; 285: 2864-70.
25. Yamashita T, Ogawa S, Aizawa Y, et al. Investigation of the optimal treatment strategy for atrial fibrillation in Japan. Circ J 2003; 67: 738-41.
26. Patients with nonvalvular atrial fibrillation at low risk of stroke during treatment with aspirin: Stroke Prevention in Atrial Fibrillation HI study. The SPAF III Writing Committee for the Stroke Prevention in Atrial Fibrillation Investigators. JAMA 1998; 279: 1273-7.
27. Hart RG, Halperin JL. Atrial fibrillation and thromboembolism: a decade of progress in stroke prevention. Ann Intern Med 1999; 131: 688-95. (Review)
28. Ohara K, Inoue H, Nozawa T, et al. Accumulation of risk factors enhances the prothrombotic state in atrial fibrillation. Int J Cardiol 2008; 126: 16-21.
29. Kizer JR, Dahlöf B, Kjeldsen SE, et al. Stroke reduction in hypertensive adults with cardiac hypertrophy randomized to losartan versus atenolol: the Losartan Intervention For Endpoint reduction in hypertension study. Hypertension 2005; 45: 46-52.
30. Wyse DG, Waldo AL, DiMaroco JP, et al. A comparison of rate control and rhythm control in patients with atrial fibrillation. N Engl J Med 2002; 347: 1825-33.
31. Van Gelder IC, Hagens VE, Bosker HA, et al. A comparison of rate control and rhythm control in patients with recurrent persistent atrial fibrillation. N Engl J Med 2002; 347: 1834-40.
32. Capucci A, Santini M, Padeletti L, et al. Monitored atrial fibrillation duration predicts arterial embolic events in patients suffering from bradycardia and atrial fibrillation implanted with antitachycardia pacemakers. J Am Coll Cardiol 2005; 46: 1913-20.